SCHEMBL1999183

SCHEMBL1999183

CC1=NCCOc2c(F)cc3c(ccn3S(=O)(=O)c3ccccc3)c21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 19/20 0.41
HTR1A P08908 3/20 0.40
DRD2 P14416 2/20 0.40
HTR2A P28223 1/20 0.40
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
HTR1F P30939 2/20 0.38
HTR7 P34969 2/20 0.38
DRD3 P35462 2/20 0.38
BRD4 O60885 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1996256 0.86 HTR6 (0.49) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL1997137 0.81 HTR6 (0.46) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL1997114 0.73 HTR6 (0.46) HTR6HTR1ADRD2HTR2ADRD3
SCHEMBL1998085 0.70 HTR6 (0.44) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL13504534 0.68 HTR6 (0.54) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL22408161 0.67 HTR6 (0.52) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL2001580 0.67 HTR6 (0.44) HTR6DRD2HTR2ABRD4MEN1
SCHEMBL3616790 0.66 HTR6 (0.52) HTR6HTR1ADRD2HTR1DHTR1B
SCHEMBL3610992 0.66 HTR6 (0.49) HTR6HTR1ADRD2HTR2AHTR1D
SCHEMBL3620082 0.66 HTR6 (0.49) HTR6HTR1ADRD2HTR1DHTR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A HTR6 1/4885HTR1A 3/4885DRD2 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.